Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY versus DYMISTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE ALLERGY versus DYMISTA.
CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY vs DYMISTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective antagonist of peripheral histamine H1 receptors. It inhibits the H1 receptor-mediated effects of histamine, reducing symptoms such as pruritus, sneezing, rhinorrhea, and urticaria. It also decreases eosinophil chemotaxis and adhesion molecule expression.
Azelastine is a histamine H1-receptor antagonist; fluticasone propionate is a corticosteroid with anti-inflammatory activity. The combination reduces nasal symptoms by blocking histamine receptors and inhibiting inflammatory mediators.
5-10 mg orally once daily; max 10 mg/day. For children's formulation, typical adult dose applies to patients >12 years.
One spray (137 mcg azelastine hydrochloride/50 mcg fluticasone propionate) per nostril twice daily, intranasal.
None Documented
None Documented
Approximately 8.3 hours (range 6–10 hours) in healthy adults; prolonged in renal impairment (e.g., up to 20 hours).
Azelastine: terminal half-life ~22 hours (plasma) with long-lasting antihistamine effect. Fluticasone propionate: terminal half-life ~7.8 hours (intravenous), but intranasal systemic exposure is very low.
Renal: ~60% unchanged; fecal: ~10%; minor biliary elimination.
Azelastine: ~75% renal (primarily as parent and metabolites), ~25% fecal. Fluticasone propionate: <5% renal, >95% fecal as parent and metabolites.
Category A/B
Category C
Antihistamine
Antihistamine/Corticosteroid Combination